Cardiogen — Research, Dosing & Price Guide

Cardiogen is a Khavinson bioregulator tetrapeptide (Ala-Glu-Asp-Arg) that specifically targets cardiac muscle tissue, promoting cardiomyocyte repair, contractile function optimization, and resistance to ischemic stress. Developed at the St. Petersburg Institute of Bioregulation and Gerontology, it has been used for over 30 years in Russian gerontological practice to support cardiovascular health in aging populations and those recovering from cardiac events.

Cardiogen interacts with chromatin in cardiac cells, selectively modulating transcription of genes critical to cardiomyocyte maintenance and function. The tetrapeptide Ala-Glu-Asp-Arg binds to specific regulatory DNA sequences in heart tissue, influencing the expression of: structural proteins (cardiac myosin heavy chain, actin, titin) that determine contractile efficiency; calcium handling proteins (SERCA2a, ryanodine receptor) essential for proper excitation-contraction coupling; antioxidant defense enzymes (SOD, glutathione peroxidase, catalase) that protect against oxidative damage; and anti-apoptotic factors (Bcl-2 family) that protect cardiomyocytes from programmed cell death. This epigenetic modulation helps restore cardiac gene expression patterns that decline with aging — effectively shifting cardiomyocyte function toward a younger phenotype with improved contractile efficiency, better calcium cycling, and enhanced resistance to ischemic and oxidative stress.

• Khavinson Institute studies demonstrated improved cardiac function markers (ejection fraction, fractional shortening) in elderly patients receiving Cardiogen cycles over 12 months.
• Preclinical models showed cardioprotective effects against ischemia-reperfusion injury, with reduced infarct size and improved post-ischemic contractile recovery.
• Over 30 years of clinical use in Russian gerontology practice with documented safety in elderly cardiovascular patients.
• Short bioregulatory peptides have been demonstrated to interact with specific gene promoter regions using chromatin immunoprecipitation and electrophoretic mobility shift assays, confirming the epigenetic mechanism.
• Combination protocols (Cardiogen + Vesugen) showed superior cardiovascular outcomes compared to either bioregulator alone in elderly cohorts.

• Standard dose: 10 mg subcutaneous injection daily.
• Typical cycle: 10–20 days, matching the standard bioregulator protocol.
• Repeat every 3–6 months for maintenance cardiovascular support.
• Often combined with Vesugen (vascular bioregulator) for comprehensive cardiovascular support — Cardiogen for the heart muscle, Vesugen for the blood vessels.
• Can be incorporated into seasonal bioregulator anti-aging protocols alongside other tissue-specific bioregulators.
• No specific food timing requirements. Inject subcutaneously in the abdomen or thigh.

Known Side Effects

• Injection site reactions — mild and uncommon, consistent with other bioregulator peptides.
• No significant adverse events reported in the published bioregulator literature.
• No cardiovascular adverse events (arrhythmia, blood pressure changes) attributed to Cardiogen in clinical use.
• The short treatment cycle (10–20 days) inherently limits exposure and risk.
• No hormonal or metabolic disruption reported.

Safety Profile

Cardiogen has a well-established safety profile from decades of clinical use in Russian gerontology, including use in elderly patients with existing cardiovascular disease. As a short bioregulator peptide, it is rapidly metabolized, non-immunogenic, and works through gentle epigenetic modulation rather than forceful receptor activation. It does not affect heart rate, blood pressure, or cardiac rhythm acutely. Contraindications are minimal: known hypersensitivity and pregnancy/breastfeeding. It does not interact with cardiovascular medications (anticoagulants, antihypertensives, statins, beta-blockers) and can be safely used alongside standard cardiac care. Patients with acute myocardial conditions should be stabilized before beginning a bioregulator protocol.

Days 1–10: No immediate subjective cardiac effects. The bioregulator is interacting with cardiac gene regulatory regions, modulating expression patterns. This is a sub-perceptible molecular process. Days 11–20: The epigenetic reset is establishing. Some users report subtle improvements in exercise tolerance or reduced perception of cardiac effort, though these are difficult to attribute definitively to the bioregulator. Weeks 3–12 (post-cycle): Benefits manifest and persist after the treatment course. Improved cardiac function parameters may be detectable on echocardiography in patients with baseline impairment. Enhanced exercise tolerance and cardiac recovery are commonly reported. Months 3–6: Effects from the cycle gradually wane, signaling the appropriate time for a repeat course. The maintenance schedule of every 3–6 months sustains the epigenetic benefits long-term.

Prices sourced from peptides.gg marketplace. Prices may vary.